



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Julius Remenar et al.

Serial No.: 10/601,092

Group No.: 1614

Filed: 06/20/2003

Examiner:

For: PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION

Attorney Docket Number: TPIP017

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Applicants submit these documents in compliance with the duty of disclosure as defined in 37 CFR §1.56, §1.97, and §1.98. The Examiner is requested to make these citations of official record in the present application.


This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

The Information Disclosure Statement transmitted herewith is being filed *after* three months of the filing date of this national application but *before* the mailing date of the first Office action on the merits.

A copy of a PCT International Search Report from a counterpart application is enclosed.
Legible copies of all items listed in Form PTO-1449 accompany this information disclosure

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify that under 37 CFR §1.8(a) that this correspondence is being deposited on October 27 2004 with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Kristin Kaberry

statement. Cumulative patents or publications identified in the attached PCT Search Report are not enclosed.

I hereby certify that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. 37 CFR 1.97 (e) (1).

It is Applicants' understanding that no fee is due; however, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 502626.

The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

The person making this statement is the attorney who signs below on the basis of the information in the attorney's file.

Respectfully submitted,

Date Oct 21, 2004

By: 

Paul Burgess
Registration No. 53,852
Transform Pharmaceuticals, Inc.
29 Hartwell Avenue
Lexington, MA 02421
Tel. #(781) 863-7816
Fax #(781) 863-7208

